Editorial
doi: 10.1001/jamaoncol.2017.4018.
Precision Medicine and Testing for Tumor Biomarkers-Are All Tests Born Equal?
Affiliations
- PMID: 29242914
- DOI: 10.1001/jamaoncol.2017.4018
Item in Clipboard
Editorial
Precision Medicine and Testing for Tumor Biomarkers-Are All Tests Born Equal?
JAMA Oncol.
.
No abstract available
Comment in
-
Analytical Validity and Clinical Utility of Tumor Biomarkers.JAMA Oncol. 2018 Oct 1;4(10):1432. doi: 10.1001/jamaoncol.2018.1698. JAMA Oncol. 2018. PMID: 30027205 No abstract available.
Comment on
-
Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing.JAMA Oncol. 2018 Jun 1;4(6):838-841. doi: 10.1001/jamaoncol.2017.4021. JAMA Oncol. 2018. PMID: 29242895 Free PMC article.
-
Patient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests.JAMA Oncol. 2018 Jun 1;4(6):868-870. doi: 10.1001/jamaoncol.2017.4027. JAMA Oncol. 2018. PMID: 29242909 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
